Skip to main content


Latest articles

25-03-2019 | Rheumatology | News | Article

Infections tied to increased risk for Sjögren’s syndrome

Individuals with primary Sjögren’s syndrome are almost twice as likely to have experienced an infection requiring hospital care than those without, researchers report.

22-03-2019 | Rheumatology | News | Article

Deep learning algorithm shows promise for predicting RA outcomes

Findings from a proof-of-concept study suggest that deep learning models based on electronic health records may be a feasible approach for forecasting disease outcomes in people with rheumatoid arthritis.

21-03-2019 | Rheumatology | News | Article

Progressive skin fibrosis should trigger enhanced monitoring in dcSSc

Progressive skin fibrosis is significantly associated with worsening lung function and an increased risk for death among patients with diffuse cutaneous systemic sclerosis, an analysis of EUSTAR data shows.

20-03-2019 | Rheumatology | News | Article

RA disease activity linked to cognitive impairment

Rheumatoid arthritis patients with high disease activity are more likely to have cognitive impairment than those with less active disease, researchers report.

19-03-2019 | Rheumatology | News | Article

Almost half of RA patients relapse after TNF inhibitor discontinuation

Findings from a systematic review and meta-analysis suggest that nearly half of patients with rheumatoid arthritis in remission experience disease relapse after elective discontinuation of tumor necrosis factor inhibitors.

18-03-2019 | Rheumatology | News | Article

Findings question the use of acetaminophen for pain relief in OA patients

Results of a systematic review suggest that treatment with acetaminophen provides only minimal benefit compared with placebo for patients with osteoarthritis.

15-03-2019 | Rheumatology | News | Article

Certolizumab pegol shows promise for nonradiographic axSpA

The tumor necrosis factor inhibitor certolizumab pegol could be an option for patients with active nonradiographic axial spondyloarthritis and objective signs of inflammation, indicate phase III trial results.

14-03-2019 | Rheumatology | News | Article

FDA approves oral colchicine for gout flare prophylaxis

Oral colchicine has been approved by the US FDA for the prevention of flares in people with gout.

14-03-2019 | Rheumatology | News | Article

IVIG–ciclosporin combination may improve coronary artery outcomes in Kawasaki disease

Findings from the KAICA trial suggest that adding ciclosporin to intravenous immunoglobulin treatment may reduce the risk for coronary artery abnormalities among patients with Kawasaki disease.

13-03-2019 | Rheumatology | News | Article

Adding conventional DMARDs to TNF inhibitors may be beneficial for obese axSpA patients

Using conventional synthetic DMARDs in addition to tumor necrosis factor inhibitor therapy may result in an increased likelihood of clinical response among overweight and obese patients with axial spondyloarthritis, researchers report.

12-03-2019 | Rheumatology | News | Article

Tramadol linked to increased mortality risk in osteoarthritis patients

Mortality rates are significantly higher during the first year after a tramadol prescription than after prescription of common nonsteroidal anti-inflammatory drugs, but it is unclear whether the relationship is causal, say researchers.

11-03-2019 | Rheumatology | News | Article

No impact of comorbidities on efficacy, safety profiles of baricitinib in RA patients

Findings from a post-hoc pooled analysis suggest that comorbidity does not influence the efficacy or safety of baricitinib 4 mg once daily in patients with rheumatoid arthritis who have had an inadequate response to conventional DMARDs.

08-03-2019 | Rheumatology | News | Article

Consensus guidelines for management of comorbid RA, cancer examined

A systematic review of consensus recommendations for the management of rheumatoid arthritis in patients with cancer shows agreement in some areas, but highlights the need for further research into topics for which discrepancies exist.

07-03-2019 | Rheumatology | News | Article

Support for sarilumab combination therapy in pretreated RA

Findings from a systematic review and network meta-analysis indicate that adding sarilumab to conventional DMARDs may be beneficial for patients with rheumatoid arthritis and an inadequate response to either conventional DMARDs or tumor necrosis factor inhibitors.

06-03-2019 | Rheumatology | News | Article

Early TNF inhibitor initiation benefits patients with psoriatic arthritis

Initiating the tumor necrosis factor inhibitor golimumab at the same time as methotrexate almost doubles the rate of remission versus methotrexate monotherapy in patients with early psoriatic arthritis, study findings indicate.

05-03-2019 | Rheumatology | News | Article

FDA issues tofacitinib safety alert

The US FDA warns that treatment with the Janus kinase inhibitor tofacitinib at a dose of 10 mg twice daily is associated with an increased risk for pulmonary embolism and death in patients with rheumatoid arthritis.

04-03-2019 | Rheumatology | News | Article

Sustained smoking cessation may reduce excess RA risk

Maintaining a nonsmoking status for a sustained period is associated with a reduction in the excess risk for developing seropositive rheumatoid arthritis, findings suggest.

01-03-2019 | Rheumatology | News | Article

Delayed exercise interventions offer unclear benefits after TKR

The benefits of later-stage exercise programs after total knee replacement are unclear, say researchers, who found a disconnect between patient-reported outcomes and performance-based tests.

28-02-2019 | Rheumatology | News | Article

Substantial proportion of patients with JIA have ongoing disease as adults

Almost half of patients with juvenile idiopathic arthritis have ongoing active disease during early adulthood, with the burden particularly high among those with enthesitis-related arthritis, researchers report.

27-02-2019 | Rheumatology | News | Article

Add-on belimumab efficacy maintained for up to 13 years in SLE patients

Individuals with systemic lupus erythematosus who respond to belimumab plus standard of care therapy can hope to experience long-term disease control, suggests a trial in which participants received treatment for up to 13 years.

image credits